The acquisition adds a pipeline of proprietary tumor-infiltrating lymphocyte (TIL) technology and programs to Turnstone's portfolio of oncolytic virus candidates, several of which are expected to enter the clinic in 2021. TIL utilizes populations of T cells that are isolated from a patient's own tumor and are expanded and stimulated before being readministered to the patient.

The terms of the deal were not disclosed. Myst CEO TJ Langer will become Turnstone's senior vice president of cell therapy development and external innovation.

Obsidian, MD Anderson partner on solid tumor cell therapy
Obsidian Therapeutics and the University of Texas MD Anderson Cancer Center have entered a multiyear strategic collaboration for the research and development...

Focus Fund, MD Anderson support investigational cancer therapies
The Focus Fund and the University of Texas MD Anderson Cancer Center have teamed up to launch Cancer Focus Fund, an investment fund aimed at supporting...